Can Wegovy and Ozempic cause sudden vision loss?

Maybe, and the risk is not the same for every version of the drug. A large analysis of FDA safety reports found that Wegovy, the weight-loss form of semaglutide, carried a reporting risk for sudden vision loss nearly five times higher than Ozempic, the diabetes form.

Semaglutide is the active ingredient in some of the most popular medicines today. It is sold as Ozempic for diabetes, as Wegovy for weight loss, and as Rybelsus in a tablet you swallow. This study asked whether these drugs are linked to a rare problem called ischemic optic neuropathy. Some people call it an “eye stroke.” It happens when blood flow to the optic nerve is cut off. The result can be sudden, permanent vision loss in the affected eye.

What the data show

Researchers searched the FDA’s FAERS database, a huge collection of reports about side effects from medicines. They reviewed more than 30.6 million reports filed between December 2017 and December 2024. About 31,774 of those reports involved semaglutide.

The biggest surprise was the gap between the two injected versions. Wegovy carried a reporting risk for eye stroke nearly five times higher than Ozempic. That held true even though Wegovy produced far fewer total reports overall. The tablet form, Rybelsus, showed no cases at all. Men were about three times more likely than women to be affected, and men taking Wegovy showed the strongest signal of any group.

Dr. Kumar’s Take

I want to be careful here, because this is exactly the kind of finding that gets blown out of proportion. Ischemic optic neuropathy is rare, and these drugs help millions of people manage diabetes and lose weight. Nobody should panic or quit their medication after reading a headline.

That said, the pattern in this data is hard to ignore. The fact that the higher-dose, injected weight-loss version stood out, while the swallowed tablet showed nothing, tells a consistent story. It points to dose and delivery as real variables worth studying. This is a signal that deserves a proper trial, not a reason to abandon a useful drug.

Why the differences matter

The pattern points to two things: how much drug a person gets, and how it enters the body. Wegovy is given at higher doses than Ozempic because it is aimed at weight loss. That stronger “dose intensity” may push the risk up. The route of delivery also seems to matter. Both Wegovy and Ozempic are injected, but the swallowed tablet, Rybelsus, showed no cases. Taken together, these clues suggest that stronger doses delivered by injection may be the key drivers behind the signal. The sex difference adds another layer, since men, and especially men on Wegovy, stood out the most.

How strong is the evidence?

It helps to know what FAERS can and cannot tell us. It is a reporting system, which means doctors, drugmakers, and patients send in reports of side effects. That makes it powerful for spotting rare patterns across millions of records. But it cannot prove that a drug caused a problem. People with diabetes and obesity already face higher odds of eye and blood vessel trouble, so some cases may have happened anyway. Reporting can also be uneven, and a newer, heavily marketed product may simply draw more attention. This study found a strong association, not proof of cause and effect.

Practical Takeaways

Do not stop taking Ozempic, Wegovy, or Rybelsus on your own, since the benefits for diabetes and weight are well established and this study does not prove the drug causes vision loss.
If you notice sudden vision loss or a sudden change in vision in one eye, treat it as an emergency and seek care right away, as quick evaluation matters with any eye stroke.
Talk with your doctor about your personal risk, especially if you are a man on the higher-dose weight-loss version, and weigh that against the reasons you started the drug.
Ask whether your dose is appropriate for your goals, since this data suggests higher dose intensity may carry more risk than lower doses.

FAQs

Should I stop taking Ozempic or Wegovy because of this study?

No, and you should never stop a prescribed medicine based on one observational study. The data show a possible link, not proof that semaglutide causes vision loss. Ischemic optic neuropathy is rare, while the benefits of these drugs for blood sugar, weight, and heart health are well documented. If you are worried, bring this study to your doctor and make the decision together rather than quitting on your own.

What are the warning signs of an eye stroke?

An eye stroke usually causes sudden vision loss or a sudden change in vision, often in just one eye. It is typically painless, which can fool people into waiting too long to get help. You might notice a dark area, blurriness, or a missing part of your field of view that appears quickly. Any sudden vision change should be treated as a medical emergency, so do not wait to see if it clears up on its own.

Is the tablet form of semaglutide safer for the eyes?

In this analysis, the oral tablet form, Rybelsus, showed no cases of eye stroke, which is reassuring on the surface. But “no reported cases” is not the same as “proven safe.” Rybelsus may have fewer users and fewer total reports, and it is taken at different doses than the injections. The cleaner result fits the theory that lower dose intensity and the non-injected route carry less risk, but it needs direct study before anyone can call one form safer than another.

Bottom Line

A massive review of FDA safety reports found that semaglutide is linked to a rare eye stroke, and the risk is far from equal across its different forms. The high-dose weight-loss injection Wegovy carried nearly five times the reporting risk of the diabetes version Ozempic, the swallowed tablet Rybelsus showed no cases, and men were hit roughly three times more often than women. This is a strong warning signal, not proof of cause, and it points to dose and the injected route as the factors most worth watching. The smart move is to stay on your medication, know the warning signs of sudden vision loss, and talk through your personal risk with your doctor.

Read the full study